转化医学时代基于拼合原理对降脂新药研发模式的应用构想

Application of translational medicine times based on the combination principles in the research and development of new anti-hyperlipidemia drugs

高脂血症作为心脑血管病最主要的危险因素之一,给家庭和国家造成沉重负担。因发病机制较为复杂、不甚明确等原因,导致对其的治疗和控制已成为当今临床迫切需要解决的难题。近年来,人们已逐步认识到要想达到理想的降脂效果,联合用药已成为理想选择。若利用拼合原理,将两个降脂药物的基本结构拼合在一个分子中,则有望获得毒副作用小、药理效应相加的降脂新药。此应用设想,不仅可为联合用药开辟一条新的思路,也可体现联合用药新的发展趋势,更是对转化医学之新药研发模式的有力尝试。

Hyperlipidemia, as one of the primary dangerous factors of cardiovascular and cerebrovascular diseases, has made a heavy burden to the family and country. For the reasons that aetiological agent is complicated, pathogenesis is unclear, et al, the treatment and control of it has become clinical urgent need to address the problem. In recent years, people have come to realize that if they want to achieve the desired anti-hyperlipidemia effect, drug combination has become the inevitable choice. If we use combination principles which assembling two basic structure of anti-hyperlipidemia in one molecule, we will obtain the new anti-hyperlipidemia drugs with decreased toxic side effects and increased pharmacological effect. This application will not only open up a new way for drug combination, but reflect a new development trend of drug combination, as well as a powerful attempt to new drug research and development mode of translational medicine.